MeSH term
Frequency | Condition_Probility | Female | 178 | 0.0 |
Humans | 352 | 0.0 |
Pregnancy | 6 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Animals | 61 | 0.0 |
Mice | 37 | 0.0 |
Polymerase Chain Reaction | 50 | 0.0 |
Adult | 138 | 0.0 |
Aged | 74 | 0.0 |
Aged, 80 and over | 18 | 0.0 |
Gastrins/blood | 4 | 5.0 |
Hyperplasia | 7 | 1.0 |
Male | 167 | 0.0 |
Middle Aged | 117 | 0.0 |
Retrospective Studies | 8 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
DNA Mutational Analysis | 30 | 0.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
Databases | 2 | 2.0 |
Family Health | 8 | 0.0 |
Genotype | 14 | 0.0 |
*Germ-Line Mutation | 24 | 5.0 |
Multiple Endocrine Neoplasia Type 1/*genetics/pathology | 7 | 100.0 |
Neoplasm Proteins/*genetics | 61 | 5.0 |
Phenotype | 15 | 0.0 |
*Proto-Oncogene Proteins | 113 | 6.0 |
Research Support, Non-U.S. Gov't | 205 | 0.0 |
Peptides, Cyclic/therapeutic use | 2 | 50.0 |
Adolescent | 44 | 0.0 |
Child | 23 | 0.0 |
Genetic Predisposition to Disease | 10 | 0.0 |
*Genetic Screening | 9 | 4.0 |
Germ-Line Mutation | 20 | 5.0 |
Multiple Endocrine Neoplasia Type 1/diagnosis/*genetics | 11 | 100.0 |
Neoplasm Proteins/genetics | 12 | 2.0 |
*Penetrance | 2 | 6.0 |
Risk | 2 | 0.0 |
Base Sequence/genetics | 4 | 1.0 |
DNA, Neoplasm/genetics | 12 | 1.0 |
Gene Frequency | 2 | 0.0 |
*Introns | 2 | 0.0 |
Multiple Endocrine Neoplasia Type 1/*genetics | 118 | 94.0 |
Mutation/*genetics | 11 | 0.0 |
Blotting, Western | 14 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
Immunohistochemistry | 11 | 0.0 |
Pancreatic Neoplasms/*metabolism | 2 | 2.0 |
Plasmids/genetics | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Rats | 11 | 0.0 |
Transfection | 13 | 0.0 |
Tumor Cells, Cultured | 14 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 21 | 10.0 |
Loss of Heterozygosity | 40 | 4.0 |
Nucleic Acid Hybridization | 11 | 0.0 |
Prevalence | 6 | 0.0 |
Adenoma/genetics | 6 | 12.0 |
Chromosomes/ultrastructure | 2 | 6.0 |
Genetic Markers | 25 | 0.0 |
Microsatellite Repeats | 14 | 1.0 |
Pancreatic Neoplasms/genetics | 12 | 35.0 |
Parathyroid Neoplasms/genetics | 11 | 68.0 |
Cell Differentiation | 4 | 0.0 |
Genes, p53/genetics | 2 | 0.0 |
Mutation | 42 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 35 | 0.0 |
Age Distribution | 4 | 1.0 |
Comparative Study | 20 | 0.0 |
Disease Susceptibility | 2 | 0.0 |
Gene Deletion | 22 | 1.0 |
Incidence | 2 | 0.0 |
Multiple Endocrine Neoplasia Type 1/*complications/genetics | 4 | 80.0 |
Severity of Illness Index | 3 | 0.0 |
Sex Distribution | 2 | 0.0 |
Treatment Outcome | 7 | 0.0 |
Multiple Endocrine Neoplasia Type 1/*complications | 7 | 87.0 |
Chromosome Mapping | 44 | 0.0 |
*Drosophila Proteins | 7 | 0.0 |
Multiple Endocrine Neoplasia Type 2a/*genetics | 3 | 11.0 |
Proto-Oncogene Proteins/genetics | 12 | 2.0 |
Receptor Protein-Tyrosine Kinases/genetics | 6 | 4.0 |
*Loss of Heterozygosity | 13 | 3.0 |
Polymorphism, Genetic | 27 | 0.0 |
Calcium/blood | 5 | 2.0 |
Parathyroidectomy | 7 | 30.0 |
Prognosis | 7 | 0.0 |
Syndrome | 9 | 0.0 |
Genes, ras | 2 | 0.0 |
Age of Onset | 2 | 0.0 |
Child, Preschool | 14 | 0.0 |
Infant | 6 | 0.0 |
Infant, Newborn | 4 | 0.0 |
Recurrence | 3 | 0.0 |
Risk Factors | 5 | 0.0 |
Time Factors | 6 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Up-Regulation | 2 | 0.0 |
Alleles | 22 | 0.0 |
Amino Acid Sequence | 23 | 0.0 |
*Genes, Tumor Suppressor | 22 | 2.0 |
Molecular Sequence Data | 40 | 0.0 |
*Mutation | 21 | 0.0 |
Polymorphism, Single-Stranded Conformational | 30 | 1.0 |
Sequence Deletion | 6 | 0.0 |
DNA Mutational Analysis/methods | 2 | 0.0 |
DNA, Neoplasm/analysis | 11 | 1.0 |
Germ-Line Mutation/*genetics | 8 | 5.0 |
Multiple Endocrine Neoplasia Type 1/*diagnosis/*therapy | 2 | 100.0 |
Multiple Endocrine Neoplasia Type 2a/*diagnosis/*therapy | 2 | 100.0 |
Cell Division/genetics | 3 | 0.0 |
Disease Progression | 6 | 0.0 |
Insulinoma/*genetics/pathology | 2 | 50.0 |
Mice, Transgenic | 7 | 0.0 |
Multiple Endocrine Neoplasia Type 1/genetics | 18 | 72.0 |
Pancreatic Neoplasms/*genetics | 14 | 15.0 |
Adenoma/*genetics | 15 | 18.0 |
Genes, Tumor Suppressor | 25 | 2.0 |
Genetic Markers/genetics | 2 | 0.0 |
Genetic Screening/methods | 3 | 2.0 |
Microsatellite Repeats/genetics | 4 | 1.0 |
Thyroid Neoplasms/*genetics | 3 | 3.0 |
Blotting, Northern | 9 | 0.0 |
Embryo/metabolism | 2 | 1.0 |
Gene Expression Regulation | 3 | 0.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
In Situ Hybridization | 8 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Neoplasm Proteins/*genetics/metabolism | 6 | 4.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Magnetic Resonance Imaging | 8 | 0.0 |
Parathyroid Glands/pathology | 8 | 57.0 |
Parathyroid Hormone/blood | 6 | 3.0 |
Reverse Transcriptase Polymerase Chain Reaction | 13 | 0.0 |
Prospective Studies | 13 | 0.0 |
Survival Analysis | 3 | 0.0 |
Tomography, X-Ray Computed | 9 | 1.0 |
Chromosomes, Human, Pair 11 | 26 | 7.0 |
Codon, Nonsense | 2 | 1.0 |
*Homozygote | 3 | 1.0 |
Hyperparathyroidism, Secondary/*genetics | 2 | 66.0 |
Gene Expression | 7 | 0.0 |
Sequence Alignment | 7 | 0.0 |
Chromosomes, Human, Pair 1/*genetics | 2 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 19 | 7.0 |
Frameshift Mutation | 6 | 1.0 |
Genes, Tumor Suppressor/physiology | 2 | 4.0 |
Hyperparathyroidism/etiology | 3 | 30.0 |
Mutation, Missense | 8 | 1.0 |
Parathyroid Neoplasms/complications/*genetics | 2 | 66.0 |
Follow-Up Studies | 6 | 0.0 |
Probability | 2 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Base Sequence | 29 | 0.0 |
Lod Score | 6 | 0.0 |
Pedigree | 72 | 1.0 |
Penetrance | 2 | 1.0 |
Case-Control Studies | 2 | 0.0 |
Cohort Studies | 4 | 0.0 |
Apoptosis | 2 | 0.0 |
Cell Division | 8 | 0.0 |
Cell Line | 12 | 0.0 |
Cells, Cultured | 8 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Plasmids/metabolism | 4 | 0.0 |
Protein Binding | 6 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Proto-Oncogene Proteins/*genetics/*metabolism | 2 | 4.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
*Ubiquitin-Protein Ligases | 2 | 0.0 |
Lung Neoplasms/*genetics | 4 | 1.0 |
Exons/genetics | 9 | 0.0 |
Genes, Dominant/genetics | 2 | 1.0 |
*Heterozygote | 3 | 0.0 |
Mice, Knockout | 9 | 0.0 |
Precipitin Tests | 6 | 0.0 |
Transcription, Genetic/*genetics | 2 | 1.0 |
COS Cells | 8 | 0.0 |
Hela Cells | 8 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Heterozygote Detection | 3 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 10 | 5.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Two-Hybrid System Techniques | 5 | 0.0 |
Cloning, Molecular | 13 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Neoplasm Proteins/*biosynthesis/genetics | 2 | 1.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
Chi-Square Distribution | 2 | 0.0 |
Adenoma/*genetics/pathology | 3 | 11.0 |
Chromosome Aberrations | 4 | 0.0 |
Chromosome Disorders | 2 | 0.0 |
Hippel-Lindau Disease/genetics | 2 | 4.0 |
Minisatellite Repeats | 2 | 1.0 |
Pituitary Neoplasms/*genetics/pathology | 3 | 42.0 |
Carcinoid Tumor/*genetics | 4 | 80.0 |
Predictive Value of Tests | 4 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
*Thymectomy | 2 | 25.0 |
Genes, Tumor Suppressor/genetics | 7 | 4.0 |
Tumor Markers, Biological/analysis | 4 | 0.0 |
Monomeric GTP-Binding Proteins/*metabolism | 2 | 13.0 |
Mutation, Missense/genetics | 3 | 1.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Transcription Factors/*metabolism | 3 | 0.0 |
Adrenal Cortex Neoplasms/genetics | 2 | 33.0 |
Brain Neoplasms/*genetics | 2 | 1.0 |
Chromosome Deletion | 4 | 0.0 |
DNA Primers/chemistry | 6 | 0.0 |
Sequence Analysis, DNA | 26 | 0.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 3 | 0.0 |
Signal Transduction | 3 | 0.0 |
Heterozygote | 28 | 1.0 |
Hyperparathyroidism/blood/*genetics | 2 | 66.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
*Alleles | 8 | 0.0 |
Carcinoid Tumor/genetics | 2 | 40.0 |
Duodenal Neoplasms/genetics | 2 | 66.0 |
*Gene Deletion | 10 | 1.0 |
Pancreatic Neoplasms/*genetics/pathology | 5 | 12.0 |
Thymus Neoplasms/genetics | 2 | 40.0 |
Adenoma/genetics/pathology | 4 | 18.0 |
DNA Methylation | 2 | 0.0 |
Oncogenes | 4 | 1.0 |
Exons | 15 | 0.0 |
Introns | 7 | 0.0 |
Transcription, Genetic | 8 | 0.0 |
English Abstract | 12 | 0.0 |
Multiple Endocrine Neoplasia Type 1/*surgery | 2 | 100.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Adenoma/complications/genetics | 2 | 100.0 |
Cyclin D1/genetics | 2 | 3.0 |
Parathyroid Neoplasms/*genetics | 11 | 32.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Radiation Hybrid Mapping | 3 | 3.0 |
Zebrafish/*genetics | 2 | 7.0 |
Crosses, Genetic | 3 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Homozygote | 3 | 0.0 |
Hyperparathyroidism/genetics/pathology | 2 | 100.0 |
Pancreatic Neoplasms/genetics/pathology | 2 | 25.0 |
Parathyroid Neoplasms/genetics/pathology | 4 | 100.0 |
Recombination, Genetic | 5 | 0.0 |
Nuclear Family | 3 | 1.0 |
Proto-Oncogene Proteins/*genetics | 12 | 1.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 17 | 0.0 |
*Chromosomes, Human, Pair 11 | 35 | 5.0 |
Genes, Dominant | 3 | 0.0 |
Genetic Screening | 5 | 0.0 |
Aneuploidy | 2 | 1.0 |
Chromosomes, Human, Pair 1 | 2 | 0.0 |
DNA, Neoplasm/analysis/genetics | 4 | 4.0 |
Gastrinoma/*genetics | 5 | 83.0 |
Genome, Human | 4 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
*Mutation, Missense | 6 | 1.0 |
Neoplasm Proteins/*metabolism | 5 | 0.0 |
Germ-Line Mutation/genetics | 3 | 4.0 |
Haplotypes/genetics | 2 | 0.0 |
Israel | 2 | 1.0 |
Sequence Deletion/genetics | 2 | 1.0 |
Cell Transformation, Neoplastic/genetics | 3 | 1.0 |
Hybrid Cells | 8 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
*Sequence Deletion | 2 | 0.0 |
*Trans-Activation (Genetics) | 3 | 0.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Neuroendocrine Tumors/*genetics/*pathology | 2 | 100.0 |
Neuroendocrine Tumors/*genetics | 3 | 75.0 |
Multiple Endocrine Neoplasia Type 1/diagnosis/genetics | 2 | 100.0 |
DNA Primers | 9 | 0.0 |
Genes, Tumor Suppressor/*genetics | 6 | 1.0 |
Intraoperative Care | 2 | 8.0 |
Genes, Tumor Suppressor/*physiology | 2 | 1.0 |
Promoter Regions (Genetics)/physiology | 2 | 1.0 |
Autoradiography | 5 | 0.0 |
DNA/chemistry | 5 | 1.0 |
Pituitary Neoplasms/*genetics | 15 | 62.0 |
*Gene Expression Regulation | 3 | 0.0 |
Organ Specificity | 4 | 0.0 |
Chromatin/metabolism | 3 | 1.0 |
RNA/metabolism | 2 | 0.0 |
Gastrinoma/genetics | 4 | 100.0 |
Hyperparathyroidism/*genetics | 14 | 35.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
*Founder Effect | 3 | 2.0 |
Haplotypes | 13 | 0.0 |
Japan | 9 | 0.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Loss of Heterozygosity/genetics | 5 | 3.0 |
Pituitary Neoplasms/genetics | 7 | 70.0 |
DNA/genetics | 8 | 0.0 |
Prolactinoma/genetics | 3 | 75.0 |
*Point Mutation | 3 | 0.0 |
Cell Cycle | 2 | 0.0 |
Reference Values | 2 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Cyclin D1/*genetics/metabolism | 2 | 10.0 |
Forecasting | 2 | 0.0 |
Hyperparathyroidism/*genetics/metabolism | 2 | 66.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Dosage Compensation (Genetics) | 3 | 2.0 |
Multiple Endocrine Neoplasia Type 1/*genetics/metabolism | 2 | 66.0 |
Hyperparathyroidism/genetics | 7 | 63.0 |
Insulinoma/genetics | 3 | 42.0 |
Mutation, Missense/*genetics | 2 | 1.0 |
Restriction Mapping | 6 | 0.0 |
*Chromosome Mapping | 15 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Neoplasms/genetics | 2 | 1.0 |
Multiple Endocrine Neoplasia Type 1/blood/*genetics | 4 | 100.0 |
Stomach Neoplasms/genetics | 2 | 8.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Neoplasm Proteins/chemistry/*genetics | 4 | 13.0 |
Multiple Endocrine Neoplasia Type 1/*genetics/*pathology | 2 | 100.0 |
3T3 Cells | 4 | 0.0 |
Fibroblasts/cytology | 3 | 1.0 |
Mice, Nude | 2 | 0.0 |
Alternative Splicing/*genetics | 2 | 1.0 |
DNA, Complementary/isolation & purification | 3 | 1.0 |
DNA, Complementary/chemistry | 2 | 1.0 |
Chromosome Banding | 3 | 0.0 |
Karyotyping | 4 | 0.0 |
DNA Probes | 4 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 10 | 0.0 |
*Chromosome Deletion | 12 | 1.0 |
Transcription Factors/genetics | 2 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
*Proto-Oncogenes | 2 | 0.0 |
RNA Splicing | 2 | 0.0 |
Endocrine Gland Neoplasms/*genetics | 5 | 71.0 |
Multiple Endocrine Neoplasia/*genetics | 17 | 43.0 |
Pituitary Neoplasms/*complications | 2 | 40.0 |
Prolactinoma/*complications | 2 | 66.0 |
*Chromosomes, Human, Pair 1 | 6 | 1.0 |
*Linkage (Genetics) | 6 | 0.0 |
Polymorphism, Restriction Fragment Length | 9 | 0.0 |
Parathyroid Neoplasms/*genetics/pathology | 5 | 71.0 |
Carcinoid Tumor/*genetics/pathology | 3 | 50.0 |
Lung Neoplasms/*genetics/pathology | 2 | 2.0 |
Bromocriptine/therapeutic use | 2 | 2.0 |
Hormone Antagonists/therapeutic use | 2 | 14.0 |
DNA, Complementary | 3 | 0.0 |
In Situ Hybridization/methods | 2 | 1.0 |
Codon/genetics | 2 | 0.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Sequence Tagged Sites | 4 | 1.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Models, Genetic | 4 | 0.0 |
Neuroendocrine Tumors/*genetics/pathology | 2 | 66.0 |
Proto-Oncogene Proteins c-jun/genetics/*metabolism | 2 | 6.0 |
Amino Acid Substitution | 3 | 0.0 |
Point Mutation | 7 | 0.0 |
Adrenal Cortex Neoplasms/*genetics | 2 | 16.0 |
Hyperplasia/genetics | 2 | 9.0 |
DNA Primers/genetics | 2 | 0.0 |
Calcitonin/blood | 2 | 6.0 |
Liver Neoplasms/genetics/pathology | 2 | 14.0 |
DNA/blood/chemistry | 2 | 16.0 |
Polymorphism, Genetic/genetics | 3 | 0.0 |
Reoperation | 2 | 1.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Gene Library | 5 | 0.0 |
Species Specificity | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Angiofibroma/*genetics | 2 | 50.0 |
*Periodicity | 2 | 6.0 |
Skin Neoplasms/*genetics | 2 | 1.0 |
Linkage (Genetics) | 23 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Genes, Reporter | 3 | 0.0 |
Models, Biological | 2 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Adrenal Gland Neoplasms/genetics | 2 | 7.0 |
Gene Dosage | 2 | 0.0 |
Family | 2 | 0.0 |
Europe | 2 | 0.0 |
DNA | 3 | 0.0 |
Founder Effect | 2 | 1.0 |
Oncogenes/genetics | 2 | 2.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
Proteins/*genetics | 3 | 0.0 |
*DNA-Binding Proteins | 4 | 0.0 |
Introns/genetics | 3 | 0.0 |
*Chromosome Banding | 2 | 8.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
*Transcription Factors | 5 | 0.0 |
Age Factors | 4 | 0.0 |
Hyperparathyroidism/complications | 4 | 80.0 |
Pancreatic Neoplasms/*genetics/metabolism/pathology | 2 | 10.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
DNA Fingerprinting | 2 | 1.0 |
Glucagonoma/*genetics | 2 | 100.0 |
Mutagenesis | 2 | 0.0 |
Cosmids | 5 | 1.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Insulinoma/*genetics | 3 | 60.0 |
Phosphoprotein Phosphatase/*genetics | 2 | 5.0 |
Protein-Serine-Threonine Kinases/*genetics | 2 | 0.0 |
*Cloning, Molecular | 2 | 0.0 |
Chromosomes, Artificial, Yeast | 3 | 0.0 |
Cosmids/genetics | 3 | 5.0 |
Multiple Endocrine Neoplasia Type 1/genetics/*pathology | 2 | 100.0 |
Chromosomes, Bacterial | 2 | 5.0 |
Duodenal Neoplasms/*genetics | 2 | 66.0 |
Chromosomes, Human, Pair 2 | 2 | 1.0 |
Hyperparathyroidism/complications/*genetics | 2 | 66.0 |
Multiple Endocrine Neoplasia Type 1/complications/genetics | 2 | 100.0 |
Acromegaly/genetics | 4 | 80.0 |
Duodenal Neoplasms/surgery | 2 | 100.0 |
Gastrinoma/surgery | 3 | 100.0 |
Phospholipase C/biosynthesis/*genetics | 2 | 100.0 |
Jaw Neoplasms/*genetics | 2 | 15.0 |
Crossing Over, Genetic | 2 | 2.0 |
Insulinoma/surgery | 2 | 100.0 |
Parathyroidectomy/methods | 2 | 100.0 |
Genes, Recessive/genetics | 2 | 2.0 |
GTP-Binding Proteins/*genetics | 2 | 1.0 |
Multiple Endocrine Neoplasia Type 1/blood/*genetics/*pathology | 2 | 100.0 |
Multiple Endocrine Neoplasia Type 1/*pathology | 2 | 100.0 |
Phospholipase C/genetics | 2 | 25.0 |
Phosphorylases/genetics | 2 | 33.0 |
Algorithms | 2 | 0.0 |
Multiple Endocrine Neoplasia Type 1/enzymology/*genetics | 2 | 100.0 |
Blotting, Southern | 4 | 0.0 |
*Lod Score | 2 | 5.0 |
Cyclin D1 | 2 | 1.0 |
DNA/analysis | 2 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Aldosterone/*secretion | 2 | 22.0 |
Centromere | 2 | 2.0 |
Multiple Endocrine Neoplasia/genetics | 2 | 15.0 |
Growth Hormone/*secretion | 2 | 1.0 |
Cushing Syndrome/*etiology/genetics | 2 | 100.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
*Chromosome Aberrations | 3 | 0.0 |
*Genetic Markers | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
*Gene Amplification | 2 | 0.0 |
Chromosome Fragility | 3 | 5.0 |
*DNA Probes | 2 | 4.0 |
Integrases/genetics | 2 | 9.0 |
Viral Proteins/genetics | 2 | 3.0 |
Carcinoma/*genetics | 2 | 1.0 |
Multiple Endocrine Neoplasia Type 1/complications | 2 | 100.0 |
Postoperative Care | 2 | 2.0 |
Insulin/blood | 2 | 0.0 |
Receptors, Calcium-Sensing | 2 | 3.0 |
